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Abstract 
Objective: To provide an up to date review of oxidative stress biomarkers in multiple sclerosis and 
thus identify candidate molecules with greatest promise as biomarkers of diagnosis, disease activity 
or prognosis. 
Method: A semi-systematic literature search using PubMed and other databases. 
Results: Nitric oxide metabolites, superoxide dismutase, catalase, glutathione reductase, inducible 
nitric oxide synthase, protein carbonyl, 3-nitrotyrosine, isoprostanes, malondialdehyde and products 
of DNA oxidation have been identified across multiple studies as having promise as diagnostic, 
therapeutic or prognostic markers in MS. 
Conclusion: Heterogeneity of study design, particularly patient selection, limits comparability across 
studies. Further cohort studies are needed, and we would recommend promising markers be 
incorporated into future clinical trials to prospectively validate their potential.  
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Introduction 
Despite major advances in understanding multiple sclerosis (MS) pathophysiology and therapeutics, 
there remains a need for better biomarkers of disease activity, therapeutic response and prognosis. 
Clinical disability scores such as the Expanded Disability Scale Score (EDSS), lack sensitivity and their 
use in trials for progressive MS are limited by the lengths of time required to detect meaningful 
disability progression. Other scores [1] developed to address these shortcomings have their own 
limitations. Magnetic resonance imaging (MRI) markers of disability progression such as brain 
atrophy attempt to improve on this but have a poor predictive value [2].  There remains a need for 
sensitive markers of disease activity, closely related to the underlying neuropathology and predictive 
of disability progression. 
 
Genomic [3], metabolomic [4] and proteomic [5] approaches to MS biomarkers hold promise. 
Profiles of putative markers are compared between groups to identify a profile of diagnostic or 
prognostic value. These techniques generate large data sets requiring tailored multivariate statistical 
analysis. Individual markers of high predictive value are seldom identified, and the physiological 
implications are frequently unclear. MicroRNAs, small non-coding RNAs which regulate post-
transcriptional gene expression, are an emerging group of micromolecules with potential as 
biomarkers in MS [6].  
 
Studies of specific metabolic pathways identified to be relevant to MS pathogenesis provide another 
approach to biomarker identification. For example, the kynurenine pathway, the major degradative 
pathway for tryptophan, has been shown to regulate immune function. Studies show kynureinine 
acid, a neuroprotective metabolite, is increased in the CSF of MS patients following relapses [7]  . 
 
Oxidative damage to DNA, protein and lipids, is a major feature of MS neuropathology in both 
relapsing-remitting and progressive disease [8]. Reactive oxygen species (ROS) (Figure 1), the 
mediators of oxidative damage, are released as part of the respiratory burst of activated neutrophils, 
monocytes and microglia and result in oligodendrocyte injury and axonal damage. Immune system 
activation usually occurs in response to pathogens, but in MS, auto-reactive T-cells initiate and 
maintain a maladaptive response to central nervous system (CNS) targets.  Major enzymes in ROS 
detoxification are superoxide dismutases (SOD) and peroxidases (including catalase) as illustrated in 
Figure 2. 
 
Regulation of antioxidant defences is a key determinant of the cytosolic redox environment. Nuclear 
factor erythroid 2 (NFE2)-related factor 2 (Nrf2) is a principal transcriptional regulator of genes with 
antioxidant effect [9]. Other transcription factors with antioxidant effect such as peroxisome 
proliferator-activated receptor (PPAR)-gamma coactivator-1α (PGC-1α) have also been implicated in 
MS pathogenesis [10]. The Nrf2 pathway has been implicated as the target of dimethyl fumarate, a 
recently licenced disease modifying therapy in relapsing-remitting MS (RRMS) [11, 12]. 
  
There is evidence from other inflammatory disorders, such as rheumatoid arthritis and systemic 
lupus erythematosus, that oxidative stress biomolecules can be surrogates of disease activity. In 
rheumatoid arthritis, plasma thioredoxins show particular promise as they prospectively track 
disease activity and correlate with C-reactive protein, a marker of disease activity [13].  
 
The biomarker challenge in MS is in many ways more significant, as the substrate of disease – the 
CNS is less accessible, and definite clinical outcomes are reached only after years of disease. 
Identifying sensitive markers which prospectively track disease activity or predict outcomes would 
thus transform clinical management.  
 
We review and summarise the evidence on major oxidative stress biochemical markers in MS. We 
consider specifically whether the evidence supports a diagnostic, disease activity monitoring, 
therapeutic monitoring or prognostic role for these molecules. We focus on studies measuring 
markers in accessible tissue fluids such as peripheral blood and cerebrospinal fluid (CSF). We review 
enzymatic antioxidants and do not consider non-enzymatic antioxidants in this review. We highlight 
the most promising oxidative stress biomarkers and implications for future research. 
Methods 
We searched PubMed (http://www.ncbi.nlm.nih.gov/pubmed) in December 2015 using the 
following search terms: ‘multiple sclerosis’ AND [carbonyl, catalase, glutathione peroxidase, 
glutathione reductase, hydrogen peroxide, iNOS, malondialdehyde, myeloperoxidase, nitrates, nitric 
oxide, nitric oxide synthase, nitrites, Nrf2, PGC, PPAR, reactive oxygen species, superoxide, 
superoxide dismutase, nitrotyrosine]. RI reviewed the titles and abstracts of articles with regard to 
our remit and selected studies for inclusion (Table 1 and Appendix). Additional relevant publications 
were identified from the references of selected articles and from focused searches of other 
databases such as Google Scholar (https://scholar.google.co.uk/). 
 
One major problem when reviewing biomarker studies was the disparity of terminology used to 
describe various types or phases of MS. In general, we have included studies on patients with 
clinically isolated syndromes (CIS) / RRMS who fulfil revised McDonald criteria [14] and studies on 
patients with progressive MS who fulfil criteria established by Lublin and Reingold [15], or relevant 
antecedent criteria. In addition, there was variation in how authors defined disease activity and 
relapses with the potential to confound results. We have reflected on these disparities, where 
relevant, throughout our discussion. 
 
Most articles reported single centre cross-sectional studies with significant heterogeneity in the 
choice of control group, patient group, biological sample, assay method and statistical method. We 
considered in general terms the quality of the evidence and implications for future research. Unless 
otherwise stated, results reached statistical significance. 
 
CSF and peripheral blood were commonly sampled in the search for biomarkers of disease, reflecting 
the systemic autoimmune basis of MS, and the biological compartmentalisation of the CNS. 
Reactive Oxygen Species 
ROS are free radical or non-radical species which oxidise biological molecules. We include nitrogen-
based oxidants in this definition, sometimes referred to as ‘reactive nitrogen species’. Most ROS 
have a very short half-life and are highly reactive, so direct quantification in biological tissues is 
difficult.  
Nitric oxide 
NO is mainly produced through a nitric oxide synthase (NOS) catalysed reaction of L-arginine and 
oxygen (Figure 1) and acts in autocrine and paracrine signalling pathways. Three isoenzymes exist in 
humans and of these inducible NOS (iNOS) is expressed in response to immune activation and is the 
major producer of NO. Subsequent oxidation produces nitrate and nitrite, more stable end-products 
which reflect NO production. 
Peripheral blood 
Cross-sectional studies have measured nitrate (NO3-) and nitrite (NO2-), often as a total value (tNOx) 
in plasma or serum. Most studies reported significantly higher mean tNOx in RRMS compared to 
control groups, in acute relapse and in remission [16-23]. Most noteworthy is Tavazzi et al.’s study 
[16] of a large cohort of 113 RRMS patients in whom serum tNOx levels were significantly higher 
(p<0.001) in RRMS patients than in health controls. Three studies described no significant difference 
but were heterogeneous as to the MS disease phenotype, and none considered patients following 
an acute relapse [24-26]. A single study [27] found the opposite: significantly lower mean tNOx in 
RRMS patients compared to control groups; no significant study characteristics were identified to 
explain this disparity. tNOx has been considered across RRMS and SPMS groups with mixed results – 
one study reported significantly higher mean tNOx in RRMS than SPMS [22] whereas others reported 
no significant difference [16, 17, 23]. 
 
Cross-sectional studies considering tNOx in relation to EDSS [16, 20] or disease duration [20] 
reported no significant relationship. A longitudinal study found higher tNOx significantly correlated 
with lower relapse rates over an 18 month period, supporting a prognostic role [22]. 
 
Stępień et al. [28] reported the effect of 3 years of interferon (IFN)-β1a and β1b treatment on serum 
nitrite. They found a significant reduction in mean serum nitrite levels (p<0.0001), along with a 
reduction in relapse rates with treatment. In the absence of a control group, it is not possible to 
directly ascribe these changes to a treatment effect, but serum nitrite may be a marker of disease 
activity.  
CSF 
Most studies of CSF reported significantly higher mean CSF tNOx in active RRMS [19, 29-31], mixed 
MS populations [32-40] and PPMS [25] compared to controls, supporting a role for tNOx as a 
diagnostic marker. In one study, mean CSF tNOx was significantly higher in RRMS than SPMS groups 
[33], supporting a role for tNOx as a marker of inflammatory disease activity. Two studies described 
no significant difference in CSF tNOx between MS and control groups but neither offered details on 
the disease activity of their patient populations [24, 26]; case-mix differences may account for the 
disparity in the outcomes of these studies. Overall, there is good evidence for tNOx as a diagnostic 
marker in MS, particularly in acute MS relapse. 
 
The potential of tNOx as a biomarker of disease activity has been explored in cross-sectional and 
longitudinal studies. Studies have reported significant association between high tNOx and the 
number of gadolinium-enhancing lesions [19], as well as the volume of gadolinium-enhancing lesions 
[32]  (51 MS patients, 14 healthy controls, p=0.01).  The longitudinal arm of the latter study [32]  
found higher baseline CSF tNOx in patients with EDSS disability progression when compared to stable 
disability (p=0.02). Cross-sectional studies reported higher CSF tNOx in patients with acute relapsing 
disease, compared to those with stable remitting disease [37, 38], and higher mean CSF nitrite in 
RRMS than progressive MS (PMS) groups [33]. One study reported higher tNOx immediately 
following relapse when compared to remission [41]. Another reported a negative correlation 
between post-relapse tNOx and the EDSS decrease at 8 weeks [29], however changes in EDSS over 
short periods of time should be interpreted with caution. Studies using heterogeneous methods 
however, failed to identify a significant relationship between tNOx and disease subtype [35], disease 
activity [34] or disability [36]. 
Other 
A single study of urinary tNOx [42] reported elevated tNOx/creatinine quotients in patients with 
demyelinating disease compared to healthy controls (p<0.0001), and in patients with clinically 
isolated syndrome (CIS) or RRMS when compared to PMS (p=0.006). 
Summary 
The evidence strongly supports raised serum, plasma and CSF tNOx, as diagnostic markers in multiple 
sclerosis, especially in patients with acute relapsing disease. Despite the aforementioned limitations, 
Stępień et al.’s work [28] suggests serum nitrite is a marker of disease activity. 
 
CSF tNOx may be a surrogate for inflammatory disease activity, and may differentiate disease 
phenotypes. A single study suggests urinary tNOx is similarly elevated in MS. 
Transcriptional Regulators of Reactive Oxygen Species 
Nrf2 is constitutively bound to cytoplasmic Kelch-like erythroid cell-derived protein with Cap’n’Collar 
homology-associated protein 1 (KEAP-1) which serves to prevent its nuclear translocation, and 
targets Nrf2 for ubiquitin-proteasome degradation. The transcriptional targets of Nrf2 are genes 
with the antioxidant response element (ARE) promoter, or homologous polymorphisms. These 
include catalase, glutathione peroxidases (GPx), glutathione reductase (GRx), glutathione S-
transferase and SOD isoenzymes. 
 
A single study measured peripheral blood mononuclear cell (PBMC) Nrf2 as part of a 14 month 
longitudinal study of 22 patients on natalizumab, an alpha4 integrin receptor blocker. In association 
with clinical improvement, Nrf2 protein expression was elevated in the cytoplasmic and nuclear 
fractions of PBMCs [43]. The interpretation of these findings is challenged by the absence of a 
control group, but the evidence suggests a role for Nrf2 in therapeutic monitoring. 
 
PGC1-α expression is reduced in normal appearing MS grey matter and this reduction is associated 
with neuronal loss [10]. A single study reported an increase in PPARγ in MS CSF compared to 
controls [44]. 
Summary 
Despite in vitro and animal model evidence for these transcriptional regulators of antioxidant 
defence as relevant to disease, few published studies have explored them in human subjects with 
MS. The discovery of an Nrf2-dependent mechanism of action for dimethyl fumarate reinforces the 
importance of work on this area. 
 
Reactive Oxygen Species Enzymes 
Phagocyte myeloperoxidase (MPO) catalyses the production of hypochlorous acid (a potent oxidant) 
from hydrogen peroxide (H2O2). Enzymatic detoxification of superoxide is through the actions of 
SODs and peroxidases (Figure 2), and for nitric oxide is through caeruloplasmin-catalysed oxidation 
to nitrite. No studies were identified measuring NADPH-oxidase in tissue fluids as a biomarker in MS. 
Myeloperoxidase 
Three studies considered mean peripheral blood MPO expression by diagnostic group with mixed 
results. Minohara et al. [45], in a cohort of 86 Japanese MS patients reported significantly higher 
serum MPO expression when compared to healthy controls. Tasset et al. [46] also found mean MPO 
expression in peripheral leukocytes higher in RRMS than in control groups though this did not reach 
statistical significance. Mostert et al. [18] measured MPO activity in peripheral leukocytes and found 
reduced mean activity in a mixed group of MS patients compared to controls. Though discrepant 
with the findings of studies of MPO expression, no single study reported on both MPO expression 
and activity. Further work is needed to clarify whether MPO is a useful biomarker in MS. No studies 
of myeloperoxidase in MS patient CSF were identified. 
Superoxide dismutases 
In humans there are three SOD isoenzymes: dimeric copper or zinc co-ordinated SOD1 (Cu/ZnSOD) in 
the cytoplasm, tetrameric manganese-coordinated SOD2 (MnSOD) in mitochondria and tetrameric 
extracellular copper or zinc co-ordinated SOD3. 
 
SODs are implicated in MS pathogenesis, as part of a physiological response to oxidative stress and 
may be therapeutic targets. An EAE mouse model study, for example, found suppressing SOD activity 
increased tissue injury, and over-expressing SOD reduced injury with reduced disability [47]. An in 
vitro study of human mesenchymal stem cell mechanisms of neuronal protection identified SOD3 
expression as necessary for the neuroprotective effect [48].  
Blood 
Studies considering SOD activity in erythrocyte lysates reported significantly higher mean activity in 
RRMS compared to control groups [49, 50], in keeping with a diagnostic role. The strongest evidence 
for this arises from Ljubisavljevic et al.’s cross-sectional study [50] of 50 CIS and 57 RRMS patients. 
Not only did they find higher SOD activity in RRMS than controls (p=0.009), they also reported higher 
SOD activity in their CIS group when compared to RRMS (p<0.05). In further analysis they identified 
CIS and RRMS patients with lower EDSS had lower SOD activity, and CIS patients with more 
gadolinium enhancing MR lesions had lower SOD activity. 
 
Longitudinal studies have explored how mean SOD activity changes during treatment interventions. 
Mitosek-Szewczyk et al. [51] considered changes in corticosteroid-treated acute relapse and showed 
mean erythrocyte SOD activity was significantly lower in RRMS immediately following relapse than in 
control groups (p<0.05), increased following IV methylprednisolone treatment and remained 
significantly higher during remission than in control groups. Tasset et al. [43] measured mean 
erythrocyte SOD activity before and after 14 months of natalizumab treatment; they found no 
significant difference, despite post-treatment reductions in carbonylated protein and oxidised 
guanosine, end products of oxidative stress. Damiano et al. [52] measured PBMC SOD1 protein and 
mRNA expression before and after 3 months of IFN-β1b treatment, confirming significantly lower 
mean baseline SOD1 expression in MS compared to control groups (p<0.001), with significantly 
increased expression following treatment. These studies suggest SOD activity varies during relapse, 
and SOD expression may be a marker of IFN-β1b treatment response. Adamczyk-Sowa et al. [53] 
reported on a complex study of MS patients receiving melatonin supplements, with mixed results; 
IFN and glatiramer acetate, but not mitoxantrone were associated with increased serum SOD activity 
(p<0.05). An earlier article [54] showed elevated CSF and serum MnSOD but reduced CSF Cu/Zn SOD 
in RRMS compared to controls, and a treatment effect for mitoxantrone. 
 
Acar et al. [55] and Ljubisavljevic et al. [56] reported mean SOD activity in serum/plasma and 
confirmed this was significantly higher in RRMS compared to control groups. Inarrea et al. [57] 
measured platelet SOD1 and SOD2 activity in MS and found no significant difference between 
groups.  
CSF 
Two studies of CSF SOD expression and activity were identified suggesting a diagnostic and 
prognostic role for this marker. Ljubisavljevic et al. [56] measured CSF and plasma SOD activity in CIS, 
RRMS and control groups. They found reduced CSF SOD activity in CIS (p<0.05) and RRMS patients 
(p<0.05) compared to controls. In contrast, plasma SOD activity was increased in CIS (p<0.05) and 
RRMS (p<0.05) compared to controls. They identified a negative correlation between SOD activity 
and EDSS suggesting SOD activity may be a surrogate for disability outcomes. Damiano et al. [52] 
also found significantly reduced mean SOD1 expression in RRMS compared to control groups. 
Summary 
Peripheral blood studies of SOD activity strongly and consistently support a role as a diagnostic 
marker in MS. More work is needed to determine whether SOD has potential as a surrogate for 
disease activity or disability outcomes. 
 
The finding of reduced CSF SOD activity in MS in contrast to increased activity in peripheral blood 
defies a straightforward explanation. This highlights a need for caution in extrapolating findings 
between biological tissues and fluids, and the need for further work to understand the changes in 
SOD isoenzyme expression in MS. 
Catalase 
Catalase is a ubiquitously expressed peroxisomal enzyme and is a major intracellular peroxidase. 
Expression is high in active demyelinating plaques and in MS grey matter astroglia [58]. In support of 
a protective role, a mouse optic neuritis model showed overexpression of catalase reduced optic 
nerve injury [59]. 
Blood 
Few studies have looked at peripheral blood catalase activity in MS, with equivocal results. Jensen & 
Clausen [60] measured catalase activity in lymphocyte and granulocyte lysates. They found lower 
activity in MS patient granulocytes compared to controls (p<0.05), but no difference within 
lymphocytes. Others looked at catalase activity in erythrocyte lysates [61] and found no difference 
between MS and control groups. None of these studies detailed disease activity in their MS 
populations making comparisons difficult. 
 
Ljubisavljevic et al.’s [56] aforementioned study also measured plasma catalase activity in CIS, RRMS 
and control groups. They reported CSF and plasma catalase activity to be increased in CIS (p<0.05) 
and RRMS patients (p<0.05) compared to controls. In support of a role in monitoring disease activity, 
they found patients with lower EDSS had higher CSF and plasma catalase activity. 
CSF 
A number of studies across mixed MS populations considered CSF catalase activity and confirmed 
increased catalase activity in MS cohorts compared to controls [54, 56, 62], supporting a diagnostic 
role.  
Summary 
There is evidence from a single study for plasma catalase activity as a diagnostic biomarker in MS. 
Plasma catalase activity may also be a marker of disease activity. The evidence in other blood 
fractions was disparate and likely confounded by variations in case-mix.  In CSF, results were more 
consistent, with good evidence in support of catalase activity as a diagnostic marker in MS. 
Glutathione Peroxidase 
Glutathione peroxidases (GPx) are selenoproteins which catalyse the reduction of peroxides through 
the oxidation of glutathione. Isoenzymes are preferentially expressed in specific tissues and have 
differing substrate affinity. GPx1 is the most abundant intracellular isoenzyme and GPx3 
predominates in plasma. 
 
Glutathione peroxidases are implicated in MS pathogenesis and for example GPx1 is upregulated in 
MS plaques. EAE rat model studies showed elevation of GPx3 in CSF compared to controls [63]. 
Blood 
Peripheral GPx activity in erythrocyte, granulocyte, lymphocyte and plasma fractions has been 
considered with mixed results. Within erythrocytes, most authors reported significantly lower mean 
GPx activity in MS compared to control groups [46, 64-67];  though the MS populations were mixed 
and many were in remission. Zachara et al. [68] in a study of MS patients with an acute relapse 
however found significantly higher mean erythrocyte GPx activity in their MS group compared to 
controls (p<0.01). 
 
Studies of lymphocytes reported mixed results. In a study of MS patients, most of whom where in 
remission, GPx levels were significantly lower than in controls [69] (p<0.05), and in another, in which 
half the patients were sampled after an acute relapse, there was no significant difference [70] 
between MS and control subjects. Case-mix differences may thus explain this discrepancy. Jensen et 
al. [69] also looked at granulocyte GPx activity, finding a significantly lower activity in their MS 
cohort compared to controls (p<0.05). 
 
One study examining serum GPx [71] found significantly increased mean GPx in RRMS patients 
compared to controls (p<0.05). Another study, of 101 RRMS patients [72] found the opposite, 
though 65% of participants were on disease modifying treatment. 
CSF 
Two studies explored CSF GPx activity in MS and control groups with inconsistent results. Calabrese 
et al. [73] compared MS patients to healthy volunteers and found significantly lower mean GPx 
activity in MS. Kaplan et al. [74] compared MS patients to dementia and stroke cohorts, reporting no 
significant differences. 
 Summary 
GPx activity studies have been performed across a range of biological tissues and patient 
populations with mixed results. Methodological differences alone are unlikely to account for these 
disparities. More work is needed to clarify whether GPx has potential as a diagnostic marker in MS. 
Glutathione Reductase 
Glutathione reductase (GRx) is an important enzymatic regulator of intracellular oxidative stress. By 
catalysing the reduction of glutathione disulphide to glutathione, the latter antioxidant is 
regenerated. 
Blood 
We identified one study of GRx activity in blood [69] which compared MS patients to healthy 
controls. No significant differences were seen in lymphocyte and granulocyte lysates, though a trend 
to lower activity in MS was described. Interestingly, a significant correlation between GPx and GRx 
activity in controls was noted, which was absent in MS patients. 
CSF 
A study of CSF GRx in 24 MS patients and controls [73] found significantly higher mean GRx activity 
in MS compared to control groups; GPx activity was found to be reduced. 
Summary 
There is a paucity of studies of GRx in MS and, at present, the evidence does not endorse a clear role 
for GRx as a biomarker in MS. A single study supports CSF GRx as  a diagnostic marker in MS. 
Inducible Nitric Oxide Synthase 
The relationship between inducible nitric oxide synthase (iNOS) and the pathogenesis of MS is 
complex, likely reflecting its dual role in signalling and tissue injury. The case for a pathogenic role is 
built by studies showing iNOS is expressed in acute MS plaques [75]. This is supported by 
correlations in animal models between iNOS burden and disease activity [76]. The evidence against a 
purely pathogenic role arises from EAE studies showing iNOS inhibition results in increased disease 
severity [77]. 
Blood 
We identified one study [78] of iNOS in lymphocytes from 15 MS patients, mostly with active 
relapsing disease, compared to controls which found increased activity and expression in the MS 
group. 
CSF 
Calabrese et al. [62] measured CSF iNOS expression and activity in RRMS patients in remission and 
controls. They found iNOS expression to be restricted to MS patients, and mean NOS activity 
significantly higher in MS (p<0.05), and abolished by iNOS inhibitors. These findings were associated 
with elevated tNOx in keeping with a nitrosative stress hypothesis. 
Summary 
There is a paucity of studies exploring iNOS as a biomarker in MS. The limited evidence supports 
iNOS as a diagnostic marker for MS in CSF and peripheral blood lymphocytes. 
End-products of oxidation 
Protein Carbonylation 
Carbonylation of proteins is a common end-point of reactions between free radicals and proteins. 
Loss of function or aggregation may result, with consequent disruption to cellular homeostasis. The 
modified proteins are targets for ubiquitin-proteasome degradation. Protein carbonylation is part of 
the milieu of oxidative injury in MS and is present in non-lesional grey and white matter, associated 
with markers of astrocytosis [79]. 
 
Studies in plasma and serum in RRMS patients in remission using the reaction with 
dinitrophenylhydrazine products have consistently demonstrated increased protein carbonylation in 
MS compared to control groups [80-82]. One study of protein carbonylation in CSF [83] confirmed 
higher levels in a mixed MS population compared to controls (p=0.034). 
Protein Nitrosylation 
Peroxynitrous acid, a highly reactive ROS, reacts with tyrosine residues to form nitrotyrosines. Such 
post-translational modification may alter protein conformation and function with pathogenic effect. 
 
Studies have measured 3-nitrotyrosine (3-NT) in serum, plasma, peripheral leukocytes and CSF. In 
serum and plasma, authors reported significantly higher mean 3-NT in MS compared to controls [62, 
81, 84, 85], including following acute relapse [84]. A single study also reported significantly higher 3-
NT in an SPMS group compared to RRMS [81]. Conversely, Seven et al. [27] reported reduced 3-NT 
immediately following relapse and following corticosteroid treatment (p<0.001). Case mix 
differences may partly explain this discrepancy as the latter is the only study in this section in which 
all MS subjects had RRMS and were enrolled after an acute relapse. 
 
In a study of response to INF-β1b treatment, serum 3-NT was found to be significantly lower in MS 
patients compared to controls (p<0.05) [86]. Another study reported reduced peripheral leukocyte 
3-NT with glatiramer acetate treatment [85] (p<0.001) and together these findings suggests a role in 
monitoring response to therapies. 
Summary 
There is good evidence for protein carbonylation and nitrosylation as diagnostic biomarkers in MS. In 
addition, evidence supports a role in monitoring response to therapies. 
Lipid peroxidation 
Lipid peroxidation is a common consequence of oxidative stress mechanisms leading to disruption of 
cell membranes and cellular injury. Malondialdehydes (MDA) and isoprostanes are most frequently 
assayed as measures of lipid peroxidation; of these, isoprostanes may be the more appropriate 
measure as unlike MDA, isoprostanes are specific to lipid peroxidation [87]. Other end-products of 
lipid oxidation such as hexanals are less frequently measured; a single study [88] reported the use of 
hexanals in exhaled air to distinguish MS from controls. 
Isoprostanes 
Isoprostanes are prostaglandin F-like products of cyclooxygenase-independent peroxidation of fatty 
acids, such as arachidonic acid. As a group they are considered ideal measures of in vivo lipid 
peroxidation [87, 89]. 8-iso-15(S)-prostaglandin F2α is most frequently studied. 
Blood 
Studies of isoprostane levels in plasma have consistently reported increases in MS, including in 
RRMS and SPMS subtypes when compared to control groups [90, 91]. A single longitudinal study [90] 
found no evidence to support a prognostic role with regard conversion to MS, EDSS scores, multiple 
sclerosis functional composite (MSFC) scores or MRI outcomes. A cross-sectional study [92] 
identified no relationship to gadolinium enhancing lesions on MRI or time since relapse. 
CSF 
CSF studies have confirmed isoprostane levels are increased in MS compared to controls [93-96]. 
One study reported a correlation with disability [96], suggesting a role as a prognostic marker. No 
correlation was however found with MRI measures of disease activity, or time between relapse and 
CSF sampling. 
 
Malondialdehyde 
Malondialdehyde (MDA) is a mutagenic secondary aldehyde formed in the reaction between ROS 
and polyunsaturated lipids. Other aldehydes are propanal, hexanal and 4-hydroxynonenal. Reaction 
with thiobarbituric acid to form a fluorescent adduct is the basis for most quantitative assays of this 
advanced lipoxidation product. 
 
MDA is highly reactive and can form adducts with protein or DNA with deleterious effect. In MS, 
MDA is present in active inflammatory lesions as well as neurones undergoing axonal degeneration 
[8], in keeping with pathogenicity. In a rat EAE model, inhibition of MDA production was shown to 
ameliorate neurological deficit [97], supporting a pathogenic role in MS.  
Blood 
Studies of plasma or serum MDA have demonstrated higher levels in MS compared to controls, 
albeit across a mixed population of MS patients [16, 51, 55, 56, 71, 98-101]. One study [102] 
comparing 77 healthy controls to 87 patients with MS, however, reported no significant difference; 
the MS patients were however in clinical remission. Conversely, another study [103] compared 13 
MS patients to 15 controls, and found significantly lower MDA in the MS group. One study measured 
MDA in erythrocyte lysates [50] confirming a significant increase in MS compared to controls. 
 
The relationship between clinical relapse and plasma or serum MDA levels has been explored, and 
the evidence supports a role in disease activity monitoring. Mitosek-Szewczyk et al. [51] explored 
serum MDA at relapse, 5 days following the initiation of corticosteroids, in remission, as well as in 
controls. They confirmed mean MDA levels were significantly higher in RRMS than in remission; and 
higher in remission compared to controls. MDA was further elevated at relapse and lower at day 5 of 
corticosteroid treatment. This provides insight into dynamic changes in this marker of oxidative 
stress during a relapse. Ljubisavljevic et al. [56] in their study of 57 RRMS, 50 CIS and 20 controls 
considered the relationship between plasma and CSF MDA, and EDSS. They found higher CSF and 
plasma MDA in patients with higher EDSS scores (p<0.05). They also identified a significant 
correlation between CSF and plasma MDA.  
 
Two studies have looked at the effect of antioxidant supplementation on serum MDA with mixed 
results [104, 105]. Neither reported a significant change in clinical parameters such as measures of 
disease activity or disability. 
CSF 
Studies quantifying CSF MDA consistently reported higher levels in MS than in control groups across 
mixed MS cohorts [51, 56, 73, 100, 103]. 
Summary 
The evidence shows isoprostanes and MDA are elevated in MS patient plasma, serum and CSF 
compared to controls in support of a diagnostic biomarker role, and changes may track disease 
activity. 
DNA oxidation 
A single study [46] considered the potential of 8-hydroxy-2’-deoxyguanosine (8-OH2dG) as a 
diagnostic marker for MS. The authors reported elevated plasma 8-OH2dG in RRMS patients 
compared to controls, in support of DNA oxidation as a diagnostic marker. 
 
Discussion 
 
Biomarker research poses practical challenges with regard to study design such as patient selection, 
control selection, the choice of assay method, the interval of follow-up in longitudinal studies, 
outcomes to which the biomarker will be compared, and data interpretation. The heterogeneity of 
studies included in our review reflects this challenge. 
 
An ideal biomarker study would consider a homogenous population of MS patients compared to 
truly healthy controls, rather than patients with potentially confounding non-MS neurological 
illnesses. The time of sampling from clinical relapse would be defined and patients followed up for 
sufficient time to reach meaningful clinical outcomes, determined by an established measure such as 
EDSS. Samples would be collected at a specific time of day to minimise the effect of circadian 
variation, processed soon after collection to avoid degradation and assays would use methods with 
small co-efficients of variation and good reproducibility. For diagnostic biomarkers, measures of the 
utility of the test such as positive and negative predictive value, or receiver operator characteristics 
analysis would place the results in a clinical context. 
 
The majority of studies reviewed were cross-sectional in nature, the MS populations were mixed and 
information on the temporal relationship of enrolment to clinical relapse was often not reported. It 
was nonetheless, apparent for example from the nitric oxide metabolite studies, that results may 
differ solely as a result of the timing of samples in relation to relapse. Control groups, where present, 
varied and sometimes included patients with other neurological illnesses deemed to be non-
inflammatory. Data on the performance of the assay methods was often not reported and for 
diagnostic markers, the analysis often did not define predictive values or useful cut-off values. 
 
A number of oxidative stress biomolecules are identified as potential diagnostic markers across CSF 
and peripheral blood (Table 2). Serum nitrite, CSF and serum SOD, CSF and plasma catalase, serum 
and peripheral leukocyte 3-NT, CSF isoprostanes, and serum malondialdehyde may also be useful as 
surrogates of disease activity, disability progression or therapeutic response. 
 
The complex nature of oxidative and anti-oxidant mechanisms in MS coupled with disease 
heterogeneity makes the interpretation of individual biomarker studies difficult. Studies of oxidative 
stress regulators and pathways, such as Nrf2, may be more informative, not least as the Nrf2 
pathway is implicated as the target of the disease modifying agent dimethyl fumarate. Longitudinal 
studies are essential to properly evaluate biomarkers as surrogates of disease activity, therapeutic 
response or outcome. 
 
The challenge in MS of sensitive biomarkers as surrogates of diagnosis, disease activity, disability 
progression or therapeutic response remains unmet. Oxidative stress biomolecules demonstrate the 
potential to fulfil this role, but further systematic evaluation in homogeneous populations and using 
standardised methods is needed. The inclusion of the most promising biomarkers in cohort studies 
and clinical trials in MS patient populations is essential to achieving this goal. 
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Future perspective 
Currently, evaluating potential therapies in MS requires lengthy clinical trials where putative 
immunomodulators are put to the test. After 2 or more years, patients reach meaningful and 
measurable clinical endpoints, which is unsurprisingly costly and contributes to the slow pace of 
drug discovery. 
 
Over the next decade, the use of candidate biomarkers in cohort studies and trials will allow reliably 
biomarkers to be validated as sensitive measures of disease activity and therapeutic response. The 
process of selecting therapies for clinical trial will thus be foreshortened and these markers will 
eventually guide clinical management in the age of personalised therapies. The discovery of a 
specific Nrf2-dependent oxidative-stress mediated mechanism of action for dimethyl fumarate in MS 
suggests such biomarkers may well emerge from the field of oxidative stress. 
 
Executive summary 
Reactive Oxygen Species 
 Most are short-lived and difficult to measure directly in tissue fluids. 
 Nitric oxide metabolites have been shown to be elevated in MS CSF, plasma and serum, and 
may have a role in monitoring disease activity. 
Transcriptional Regulators of Reactive Oxygen Species 
 Nrf2, as a target of effective therapy in MS, is an emerging biomarker of disease activity. 
Reactive Oxygen Species Enzymes 
 Superoxide dismutase activity has been shown to be decreased in MS CSF but increased in 
plasma and serum, suggesting a role as a diagnostic marker. 
 Catalase activity has been shown to be elevated in MS CSF, plasma and serum, suggesting a 
role as a diagnostic marker. 
 Inducible nitric oxide synthase has been reported elevated in in MS CSF and in MS peripheral 
blood lymphocytes in keeping with a role as a diagnostic marker. 
End-products of Oxidation 
 Protein carbonylation and nitrosylation have been shown to be elevated in MS CSF, plasma 
and serum and may have a role in monitoring treatment response. 
 Isoprostanes and MDA have been shown to be elevated in CSF, plasma and serum, and may 
track disease activity. 
 Plasma oxidised DNA has been shown to be elevated in MS and may have a role as a 
diagnostic marker. 
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Figure Captions 
Figure 1 - Nicotinamide Adenine Dinucleotide Phosphate (NADPH)-oxidase catalyses the generation of the toxic 
superoxide (O2-) radical anion (right). Coincident transcriptional upregulation of inducible nitric oxide synthase (NOS) 
increases nitric oxide radical (NO.) production (left). NO. and O2- react to form ONOO- (orange), peroxynitrite, a highly 
toxic reactive oxygen species.  
Figure 2 – Superoxide dismutase catalyses the detoxification of superoxide to hydrogen peroxide which decomposes to 
water and oxygen, catalysed by peroxidases, in particular, catalase. Glutathione peroxidase (not shown) catalyses the 
reduction of peroxides through oxidation of reduced glutathione. 
Figure 3 - Simplified schematic representing anti-oxidant responses to reactive oxygen species (ROS) via Nrf2 and PGC1α. 
(ARE: anti-oxidant response element; PPRE: PPAR responsive element) 
 
Table Captions 
Table 1 - The review focuses on major oxidative stress markers, closely implicated in MS pathogenesis and reported in 
the literature.  
Table 2 – Oxidative stress biomarkers with diagnostic potential in MS. (-) - not enough evidence;  - increased;  - 
decreased; / - inconsistent, mixed or non-significant findings; BOLD – evidence supports a diagnostic role for this 
marker. 
 
